Shares in NeuroSearch A/S gained almost 22 percent Monday on news that its candidate obesity drug tesofensine attained an average weight reduction of about 10 ten percent in a Phase IIb clinical trial. (BioWorld International)

The early stop thanks to efficacy of Millennium Pharmaceuticals Inc.'s Phase III trial with Velcade in new multiple myeloma patients left a key question unanswered, as the firm rolls toward a supplemental new drug application in the front-line setting "as fast we can, but by the first quarter of 2008," said Deborah Dunsire, president and CEO. (BioWorld Today)